| Size | Price | Stock | Qty |
|---|---|---|---|
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| Other Sizes |
| Targets |
mGluR5 ( Ki = 156 nM ); mGluR5 ( EC50 = 9.6 nM )
mGluR5 (metabotropic glutamate receptor 5). |
|---|---|
| ln Vitro |
VU-1545 (10 and 100 μM) promotes AKT activation. VU-1545 effectively promotes Akt activation above basal levels at concentrations of 0.1 and 1.0 μM[2].
VU-1545 is a positive allosteric modulator of mGlu5 with a Ki of 156 nM and an EC50 of 9.6 nM at rat mGlu5. It promotes AKT activation at concentrations of 10 and 100 μM. |
| ln Vivo |
No detailed in vivo activity data is available for this compound. As a potent mGlu5 PAM, it is expected to have activity in models of neurological and psychiatric disorders, but specific in vivo efficacy studies have not been reported.
|
| Enzyme Assay |
The compound's binding affinity to mGlu5 is assessed in cell-free radioligand binding assays using membrane preparations from cells expressing rat mGlu5 receptors. Competition binding experiments determine the Ki value of 156 nM.
|
| Cell Assay |
Cell Line: Neuronal cells
Concentration: 10 and 100 μM Incubation Time: 5 minutes Result: Promoted Akt phosphorylation as efficiently at the concentration of 10.0 μM as at the concentration of 100.0 μM VU-1545 is evaluated in cell-based functional assays using cells expressing mGlu5 receptors. Calcium mobilization or other second messenger assays measure the compound's ability to potentiate glutamate-induced receptor activation, with an EC50 of 9.6 nM. |
| Animal Protocol |
No detailed in vivo animal experimental protocol is available for this compound. For mGlu5 PAMs, typical in vivo studies involve rodent models of anxiety, depression, or cognition to assess CNS activity.
|
| ADME/Pharmacokinetics |
No detailed pharmacokinetic data is available for VU-1545. With a molecular weight of 402.38, specific PK parameters have not been reported.
|
| Toxicity/Toxicokinetics |
No detailed toxicological data is available for this compound. As a research-grade chemical probe, standard preclinical toxicity assessments have not been published.
|
| References |
|
| Additional Infomation |
VU-1545 has a molecular formula of C22H15FN4O3 and a molecular weight of 402.38. The compound is a potent and selective positive allosteric modulator of mGlu5 that promotes AKT activation and serves as a research tool for studying mGlu5 receptor function. It has not advanced to clinical trials and is not FDA-approved.
|
| Molecular Formula |
C22H15FN4O3
|
|---|---|
| Molecular Weight |
402.3779
|
| Exact Mass |
402.113
|
| Elemental Analysis |
C, 65.67; H, 3.76; F, 4.72; N, 13.92; O, 11.93
|
| CAS # |
890764-63-3
|
| PubChem CID |
11625520
|
| Appearance |
Light yellow to yellow solid powder
|
| LogP |
5.435
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
30
|
| Complexity |
602
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1(F)=C(C=CC=C1)N1C(N(C(=O)C2=CC=C(N(=O)=O)C=C2)[H])=CC(=N1)C1=CC=CC=C1
|
| InChi Key |
BRAZLURTFMCAHU-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C22H15FN4O3/c23-18-8-4-5-9-20(18)26-21(14-19(25-26)15-6-2-1-3-7-15)24-22(28)16-10-12-17(13-11-16)27(29)30/h1-14H,(H,24,28)
|
| Chemical Name |
N-[2-(2-fluorophenyl)-5-phenylpyrazol-3-yl]-4-nitrobenzamide
|
| Synonyms |
VU1545; VU-1545; VU 1545
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.4852 mL | 12.4261 mL | 24.8521 mL | |
| 5 mM | 0.4970 mL | 2.4852 mL | 4.9704 mL | |
| 10 mM | 0.2485 mL | 1.2426 mL | 2.4852 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
|
|
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
